Statistics

Total Visits

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease9

Select a period of time:

Number of views in the range

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease6

Views

Views
November 20231
December 20230
January 20241
February 20240
March 20240
April 20241
May 20243
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
 

Top cities views

Views
Chicago2
Boardman1